Definition/General

Introduction:
-Ovarian tubular carcinoma is an extremely rare variant of ovarian adenocarcinoma characterized by well-formed tubular structures
-It represents less than 1% of all ovarian malignancies
-The term is more commonly associated with breast pathology
-Ovarian cases show tubular architecture similar to breast tubular carcinoma
-Most cases are unilateral and present at early stages.
Origin:
-Arises from surface epithelium or inclusion cysts of the ovary
-Develops through stepwise progression from benign to malignant transformation
-Shows similar molecular pathways to endometrioid adenocarcinoma
-May arise from endometriosis in some cases
-The tubular differentiation represents a specific architectural pattern rather than a distinct histogenetic origin.
Classification:
-Classified under WHO 2020 as a variant of surface epithelial tumor
-Grade I (well-differentiated) with excellent tubule formation
-Grade II (moderately differentiated) with moderate tubular architecture
-Grade III cases are extremely rare
-FIGO staging follows standard ovarian cancer protocols
-TNM classification applies with T1a-T4 stages.
Epidemiology:
-Peak incidence in 5th-6th decades (45-65 years)
-Postmenopausal women predominantly affected
-Unilateral presentation in 90% cases
-Associated with favorable prognosis
-Indian population shows similar age distribution
-Often associated with hormonal factors
-Family history of breast/ovarian cancer may be relevant.

Clinical Features

Presentation:
-Pelvic mass (most common presentation in 80% cases)
-Abdominal distension due to tumor mass
-Early satiety and abdominal discomfort
-Unilateral presentation typical (90% cases)
-Often asymptomatic in early stages
-May present as incidental finding during routine examination
-Rarely presents with hormonal symptoms.
Symptoms:
-Pelvic pain (40-50% cases)
-Abdominal bloating and distension
-Urinary frequency due to mass effect
-Constipation or bowel changes
-Early satiety and weight loss
-Menstrual irregularities (in premenopausal women)
-Postmenopausal bleeding occasionally reported.
Risk Factors:
-Age >45 years (primary risk factor)
-Nulliparity or low parity
-Late menopause (>52 years)
-Family history of breast/ovarian cancer
-BRCA1/2 mutations (rare association)
-Hormone replacement therapy
-Personal history of breast cancer
-Endometriosis (possible association).
Screening:
-Transvaginal ultrasound (first-line imaging)
-Pelvic examination with bimanual assessment
-CA-125 tumor marker (may be elevated)
-CT/MRI pelvis for staging and assessment
-PET-CT in advanced cases
-Genetic counseling for high-risk patients.

Master Tubular Carcinoma Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-Solid, firm tumor with well-defined margins
-Gray-white cut surface with areas of hemorrhage and necrosis
-May show cystic components in some cases
-Surface may be smooth or lobulated
-No papillary projections typically seen
-Cut surface shows homogeneous appearance with minimal hemorrhage.
Characteristics:
-Firm consistency similar to breast tubular carcinoma
-Gray-white to tan coloration on cut surface
-Well-circumscribed margins in most cases
-Minimal necrosis due to well-differentiated nature
-Calcifications may be present but uncommon
-Surface involvement is typically absent.
Size Location:
-Size ranges from 2-8 cm (median 4 cm)
-Unilateral involvement in 90% of cases
-Can arise from any part of ovary
-Surface involvement rare
-Bilateral disease extremely uncommon
-Usually confined to ovary at presentation.
Multifocality:
-Unifocal presentation is typical (95% cases)
-Multifocal disease within same ovary rare
-Bilateral involvement reported in <10% cases
-Extraovarian spread uncommon at presentation
-Peritoneal implants rare due to favorable biology
-Lymph node involvement uncommon in early stages.

Microscopic Description

Histological Features:
-Well-formed tubular structures lined by single layer of epithelial cells
-Open tubular lumina with minimal secretions
-Desmoplastic stroma surrounding tubules (similar to breast tubular carcinoma)
-Minimal nuclear pleomorphism
-Low mitotic activity (<5 mitoses/10 HPF)
-Absence of necrosis in well-differentiated areas.
Cellular Characteristics:
-Cuboidal to low columnar epithelial cells
-Uniform nuclear morphology with minimal pleomorphism
-Open chromatin pattern with small nucleoli
-Moderate eosinophilic cytoplasm
-Apical cytoplasm may contain secretory vacuoles
-Nuclear stratification minimal or absent.
Architectural Patterns:
-Tubular architecture predominates (>90% of tumor)
-Single-layered epithelium lining tubules
-Open lumina without solid areas
-Infiltrative growth pattern into ovarian stroma
-Desmoplastic stromal response
-Absence of papillary or solid components.
Grading Criteria:
-Grade I (well-differentiated): >75% tubular structures
-Grade II (moderately differentiated): 50-75% tubular structures
-Grade III (poorly differentiated): <50% tubular structures (extremely rare)
-Mitotic count: Grade I (<10/10 HPF)
-Nuclear pleomorphism minimal in Grade I
-Tubule formation is key grading parameter.

Immunohistochemistry

Positive Markers:
-CK7 (95-100% cases)
-PAX8 (90-95% cases - ovarian epithelial marker)
-WT1 (85-90% cases)
-CA125 (70-80% cases)
-Estrogen receptor (60-70% cases)
-Progesterone receptor (50-60% cases)
-p53 wild-type pattern typically.
Negative Markers:
-CK20 (negative)
-CDX2 (negative - excludes GI origin)
-TTF1 (negative - excludes lung primary)
-Mammaglobin (negative - helpful vs breast origin)
-GCDFP15 (negative)
-p63 (negative)
-Calretinin (negative - excludes sex cord stromal tumor).
Diagnostic Utility:
-PAX8 positivity confirms ovarian epithelial origin
-CK7+/CK20- pattern supports ovarian primary
-WT1 positivity favors serous differentiation
-Hormone receptor status guides therapy
-p53 wild-type pattern supports low-grade biology
-Negative markers exclude other primaries.
Molecular Subtypes:
-Low-grade serous-like molecular profile
-Hormone receptor positive subtype (60-70%)
-p53 wild-type pattern predominates
-Low Ki-67 proliferation index (<10%)
-BRCA pathway alterations uncommon
-Homologous recombination proficient typically.

Molecular/Genetic

Genetic Mutations:
-KRAS mutations (20-30% cases - similar to low-grade serous)
-BRAF mutations (10-15% cases)
-PIK3CA mutations (15-20% cases)
-ARID1A mutations (10-15% cases)
-TP53 mutations rare (<5% - wild-type predominates)
-BRCA1/2 mutations uncommon (<5%).
Molecular Markers:
-Hormone receptor expression (ER/PR positive in 60-70%)
-p53 wild-type pattern (>90% cases)
-Low Ki-67 proliferation index (<10% typically)
-Beta-catenin membranous pattern
-E-cadherin preserved expression
-MMR proteins intact (microsatellite stable).
Prognostic Significance:
-Favorable prognosis compared to high-grade serous carcinoma
-Stage at presentation most important prognostic factor
-Grade I tumors have excellent prognosis
-Hormone receptor positivity associated with better outcomes
-p53 wild-type indicates low-grade biology
-Early stage (I-II) has >90% 5-year survival.
Therapeutic Targets:
-Hormone receptors (endocrine therapy target)
-PARP inhibitors limited utility (HRD uncommon)
-Anti-angiogenic agents (bevacizumab)
-mTOR pathway inhibitors (investigational)
-CDK4/6 inhibitors (hormone receptor positive cases)
-Immunotherapy limited role (microsatellite stable).

Differential Diagnosis

Similar Entities:
-Endometrioid adenocarcinoma (may show tubular pattern)
-Low-grade serous carcinoma (similar morphology)
-Metastatic breast tubular carcinoma (identical morphology)
-Clear cell carcinoma (tubular variant)
-Sertoli cell tumor (tubular pattern)
-Adenomatoid tumor (benign with tubules).
Distinguishing Features:
-Ovarian tubular vs Endometrioid: Endometrioid shows squamous differentiation
-Ovarian tubular: Lacks squamous elements
-vs Breast primary: Clinical history crucial
-Mammaglobin/GCDFP15 negative in ovarian
-vs Sertoli cell: Inhibin/calretinin negative
-EMA positive favors epithelial origin
-vs Clear cell: Lacks hobnail cells.
Diagnostic Challenges:
-Distinguishing from breast metastasis most challenging
-Clinical correlation essential
-IHC panel required (PAX8, mammaglobin, GCDFP15)
-Bilateral presentation may suggest metastasis
-Morphological overlap with endometrioid adenocarcinoma
-Small biopsy samples may be insufficient for diagnosis.
Rare Variants:
-Tubular carcinoma with mucinous features
-Mixed tubular-endometrioid pattern
-Tubular carcinoma with clear cell areas
-Cystic tubular carcinoma
-Tubular carcinoma with serous features
-Each variant requires appropriate IHC workup.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

Right/Left ovary and fallopian tube, measuring [X x Y x Z] cm and weighing [X] grams

Gross Description

The ovary shows a [X] cm solid mass with [characteristics]. Cut surface reveals [appearance]. Fallopian tube appears [normal/abnormal]

Microscopic Description

Sections show well-formed tubular structures lined by single layer of epithelial cells with [nuclear features] and [mitotic activity]

Immunohistochemistry

CK7: Positive, PAX8: Positive, WT1: Positive, CK20: Negative, CDX2: Negative, Mammaglobin: Negative

Diagnosis

Ovarian Tubular Carcinoma, Grade [I/II], FIGO Stage [stage]

Staging (FIGO 2014)

T[X]N[X]M[X], Stage [I/II/III/IV]

Final Diagnosis

Right/Left Ovarian Tubular Carcinoma, Grade [X], FIGO Stage [X], with detailed staging information